Literature DB >> 8708729

Radiation in management of patients with dermatofibrosarcoma protuberans.

H Suit1, I Spiro, H J Mankin, J Efird, A E Rosenberg.   

Abstract

PURPOSE: The preferred treatment of dermatofibrosarcoma protuberans (DFSP) is wide resection, namely, margins > or = 3 cm beyond the evident disease and histologically negative margins. We assess the success achieved by radiation combined with surgery for positive/close margins or by radiation alone for those tumors that are not resectable for technical/medical reasons. The literature on this point is virtually nonexistent.
MATERIALS AND METHODS: The outcome of treatment of 18 patients with DFSP by radiation alone (n = 3) and radiation and surgery (n = 15) at the Massachusetts General Hospital was assessed. All of the lesions at the time of the treatment by radiation alone or combined with surgery were less than 10 cm. This was the maximum dimension. The actual tumor volume was much less than indicated by this maximum dimension, as the tumors were usually relatively flat.
RESULTS: The 10-year actuarial local control rate was determined to be 88%. Local control was realized in the three patients treated by radiation alone, with follow-up periods of > or = 9 years. Among 15 patients treated by radiation and surgery, there have been three local failures; the 10-year actuarial local control rate was 84%. The three local failures occurred in 12 patients whose surgical margins were positive. One of these three local failures developed in the group of two patients whose lesions were scored as grade II.
CONCLUSION: Radiation in well-tolerated dose schedules is an effective option in the management of patients with DFSP. This appears to be true for radiation alone or postoperatively for margin-positive disease (primary or recurrent).

Entities:  

Mesh:

Year:  1996        PMID: 8708729     DOI: 10.1200/JCO.1996.14.8.2365

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  17 in total

Review 1.  Targeted therapy for dermatofibrosarcoma protuberans.

Authors:  Thomas A Abrams; Scott M Schuetze
Journal:  Curr Oncol Rep       Date:  2006-07       Impact factor: 5.075

2.  [Radiotherapy is effective in the adjuvant treatment of dermatofibroma protuberans].

Authors:  R Fietkau
Journal:  Strahlenther Onkol       Date:  1998-10       Impact factor: 3.621

3.  Dermatofibrosarcoma protuberans of penis: Case report and literature review.

Authors:  Hamid Raashid; Zaroo Inaam; Hafeez Aadil; M A Darzi; Ataf Rasool; Hamid Abdul; Afrozah Akhter
Journal:  Urol Ann       Date:  2014-07

4.  Dermatofibrosarcoma protuberans with pit-like lesions: A case report and literature review.

Authors:  Jinjing Jia; Yan Zheng; Xinyu Dong; Xin Wang; Jiao Yang; Zhaoxia Ying; Yongxian Wang; Xinwu Niu; Shengxiang Xiao
Journal:  Oncol Lett       Date:  2015-09-24       Impact factor: 2.967

5.  Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.

Authors:  Piotr Rutkowski; Martine Van Glabbeke; Cathryn J Rankin; Wlodzimierz Ruka; Brian P Rubin; Maria Debiec-Rychter; Alexander Lazar; Hans Gelderblom; Raf Sciot; Dolores Lopez-Terrada; Peter Hohenberger; Allan T van Oosterom; Scott M Schuetze
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

Review 6.  Advances in the systemic treatment of cutaneous sarcomas.

Authors:  Jason J Luke; Mary Louise Keohan
Journal:  Semin Oncol       Date:  2012-04       Impact factor: 4.929

7.  Magnetic resonance imaging and mammographic appearance of dermatofibrosarcoma protuberans in a male breast: a case report and literature review.

Authors:  Xin Chen; Yung Hsin Chen; Yi-Li Zhang; You-Min Guo; Zhi-Lan Bai; Xian Zhao
Journal:  J Med Case Rep       Date:  2009-06-16

Review 8.  Current treatment options in dermatofibrosarcoma protuberans.

Authors:  Doreen Lemm; L-O Mügge; T Mentzel; K Höffken
Journal:  J Cancer Res Clin Oncol       Date:  2009-02-10       Impact factor: 4.553

Review 9.  [Dermatofibrosarcoma protuberans].

Authors:  S Ugurel
Journal:  Hautarzt       Date:  2008-11       Impact factor: 0.751

10.  Imatinib in the treatment of dermatofibrosarcoma protuberans.

Authors:  Stefanos V Labropoulos; Evangelia D Razis
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.